减少经会阴系统穿刺针数能否达到与MRI/超声融合穿刺相同的 prostate cancer 检出率?
该前瞻性研究纳入165例PI-RADS≥3患者,比较TB+SB与TB+nSB等假设方案。结果显示TB+nSB与TB+SB在前列腺癌和临床显著前列腺癌检出率上无差异,提示减少系统穿刺针数的优化采样方案可行。
要点
- TB+nSB与TB+SB在前列腺癌和csPCa检出率上无差异
- 非靶向区域MRI真阴性组与假阴性组最大癌占比差异显著
- 减少系统穿刺针数的TB+nSB方案可作为优化采样策略
核心结论
- TB+nSB方案以更少的系统穿刺针数,达到了与标准TB+SB相同的PCa和csPCa检出率。
研究设计与样本
- 前瞻性纳入至少一个PI-RADS≥3病灶的患者,每例均行TB和SB作为参考。
- 比较TB only、SB only、TB+nSB三种假设方案与TB+SB的PCa和csPCa检出率及针数。
- 共纳入165例患者。
主要发现
- 165例中107例(64.8%)经TB+SB诊断为PCa,91例(55.2%)为csPCa。
- PCa患者中非靶向区域MRI真阴性54例(50.5%)、假阴性53例(49.5%)。
- csPCa患者中非靶向区域MRI真阴性42例(46.2%)、假阴性49例(53.8%)。
- 阳性穿刺病例中最大癌占比在真阴性组与假阴性组间差异显著。
- TB+nSB与TB+SB在PCa或csPCa检出上无差异。
临床怎么用
- 对于PI-RADS≥3患者,可考虑采用TB+nSB方案以减少系统穿刺针数,同时维持PCa和csPCa检出率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to the discomfort and incidence of complications increases with the increasing number of biopsy cores, the protocol of prostate biopsy has been promoted from systematic biopsy (SB) to targeted biopsy (TB) in many studies. However, the optimal prostate sampling scheme to balance the incidence of biopsy complications and accuracy of biopsy remains controversial. Our objective is to explore an optimal prostate cancer (PCa) sampling scheme with fewer SB cores. METHODS: Patients with at least one lesion of Prostate Imaging Reporting and Data System ≥3 were prospectively enrolled. TB and SB were performed for each patient as reference. The hypothetical biopsy sampling schemes were TB only, SB only, and TB followed by SB of the nontargeted sector (TB+nSB). The PCa and clinically significant PCa (csPCa) detection rates and cores of the three hypothetical biopsy schemes were compared with TB+SB. RESULTS: Among 165 patients, 107 (64.8%) were diagnosed with PCa and 91 (55.2%) with csPCa via TB+SB. There were 54 (50.5%) and 42 (46.2%) magnetic resonance imaging (MRI) true negative cases and 53 (49.5%) and 49 (53.8%) false negative cases of nontargeted sectors among PCa and csPCa patients, respectively. The maximal cancer proportion in positive biopsy cases differed significantly between the true and false groups of these cohorts. There was no difference between TB+nSB and TB+SB for PCa or csPCa detection. CONCLUSIONS: The optimal sampling scheme TB+nSB with fewer SB cores showed same PCa and csPCa detection rates as that of standard TB+SB with MRI/ultrasound fusion biopsy.
引用
- Liu H, Ruan M, Wang H, et al. Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy? Prostate Cancer Prostatic Dis. 2020. PMID: 32719353. doi:10.1038/s41391-020-0260-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。